PMID- 28606344
OWN - NLM
STAT- MEDLINE
DCOM- 20170803
LR  - 20191210
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 120
IP  - 1S
DP  - 2017 Jul 1
TI  - EMPA-REG OUTCOME: The Endocrinologist's Point of View.
PG  - S48-S52
LID - S0002-9149(17)30800-7 [pii]
LID - 10.1016/j.amjcard.2017.05.010 [doi]
AB  - For many years, it was widely accepted that control of plasma lipids and blood 
      pressure could lower macrovascular risk in patients with type 2 diabetes mellitus 
      (T2DM), whereas the benefits of lowering plasma glucose were largely limited to 
      improvements in microvascular complications. The Empagliflozin Cardiovascular 
      Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose 
      (EMPA-REG OUTCOME) study demonstrated for the first time that a glucose-lowering 
      agent, the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, could 
      reduce major adverse cardiovascular events, cardiovascular mortality, 
      hospitalization for heart failure, and overall mortality when given in addition 
      to standard care in patients with T2DM at high cardiovascular risk. These results 
      were entirely unexpected and have led to much speculation regarding the potential 
      mechanisms underlying cardiovascular benefits. In this review, the results of 
      EMPA-REG OUTCOME are summarized and put into perspective for the endocrinologist 
      who is treating patients with T2DM and cardiovascular disease.
CI  - Copyright (c) 2017 The Author. Published by Elsevier Inc. All rights reserved.
FAU - Perreault, Leigh
AU  - Perreault L
AD  - University of Colorado Anschutz Medical Campus, Aurora. Electronic address: 
      leigh.perreault@ucdenver.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170517
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism/physiopathology
MH  - Diabetic Angiopathies/*prevention & control
MH  - Glucosides/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
EDAT- 2017/06/14 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/06/14 06:00
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/08/05 06:00 [medline]
AID - S0002-9149(17)30800-7 [pii]
AID - 10.1016/j.amjcard.2017.05.010 [doi]
PST - ppublish
SO  - Am J Cardiol. 2017 Jul 1;120(1S):S48-S52. doi: 10.1016/j.amjcard.2017.05.010. 
      Epub 2017 May 17.